A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
1. autor: | Karim, Azrin |
---|---|
Kolejni autorzy: | Islam, Farzana |
Format: | Project report |
Język: | English |
Wydane: |
Brac University
2024
|
Hasła przedmiotowe: | |
Dostęp online: | http://hdl.handle.net/10361/24372 |
Podobne zapisy
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
od: Islam, Saidul
Wydane: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
od: Ahmed, Nafisa
Wydane: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
od: Meem, Manila
Wydane: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
od: Hossain, Sadman Sanjid
Wydane: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
od: Jahan, Nusrat
Wydane: (2024)